Resources
73 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/26/2024
The Nitazenes Overview resource created by RCORP-TA describes what nitazenes are, how to determine if they are in your community, and how to prevent and respond to overdoses due to nitazenes. Additional resources are also provided to learn more about nitazenes.
Posted 3/29/2024 (updated 4/4/2024)
This session offered a review of the programmatic work of the Foundation for Opioid Response Efforts (FORE), discussed different types of funding opportunities, and then used FORE’s application process as an example of applying for and receiving funding from private foundations.
Posted 3/29/2024
A planning committee of the National Academies of Sciences, Engineering, and Medicine organized and conducted a two-day virtual public workshop that brought together data experts, program implementers and evaluators, and other key interested parties to explore data collection efforts, evidence gaps, and research needs on harm reduction for people who use drugs (PWUD).
Posted 3/28/2024 (updated 4/4/2024)
This session outlined how the Communities of Practice for Rural Communities Opioid Response Program (COP-RCORP) Consortium created a Disparities Impact Statement (DIS) that encompassed four Ohio counties (Ashtabula, Fairfield, Sandusky, and Seneca) and three HRSA grants (two RCORP-Psychostimulant grants and one RCORP-Behavioral Health Support grant).
Posted 2/9/2024 (updated 3/28/2024)
The Center for Financing Reform and Innovation (CFRI) is a SAMHSA contract that seeks to understand financing mechanisms of behavioral health care to identify opportunities, innovations, and challenges to service delivery and access. Learn about behavioral health financing mechanisms, options, and innovations through CFRI reports and webinars using the CFRI website.
Posted 12/15/2023 (updated 3/28/2024)
The Opioid-Overdose Reduction Continuum of Care Approach is a guide for policymakers for implementing evidence-based strategies that address opioid overdose.
Posted 11/7/2023 (updated 3/28/2024)
Grantees from the Implementation III & IV, Behavioral Health Support, Psychostimulant Support I & II cohorts are invited to this “re-welcome” webinar to kick-off the new project year.
Posted 10/19/2023 (updated 4/11/2024)
Implementation IV grantees with tools and strategies
Posted 9/29/2023 (updated 3/27/2024)
The 2023 RCORP-Overdose Response Onboarding Packet contains strategies and resources to assist grantees in the implementation of your new Overdose Response (OR) grant. The Onboarding Packet includes tools to support grant-funded activities, along with information on accessing TA.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.